This Stock Is Down By 13% This Year: Here's Why It's a Buy
It's been a mixed year for pharma giant Pfizer (NYSE: PFE). While the company's coronavirus-related portfolio continues to hit it out of the park, its shares have dropped by 13% since the beginning of the year. True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. The good news is that there are excellent reasons to get in on this top drugmaker at current levels. Here's why Pfizer looks like a buy right now.
Source Fool.com